title: New drugs 2014, part 2.
authors.affiliation: Remington Professor of Pharmacy Philadelphia College of Pharmacy University of the Sciences Philadelphia, Pa.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D017277:Drug Approval; D004358:Drug Therapy / Q000451:nursing*; D005341:Fibrinolysin / Q000627:therapeutic use; D006575:Heterocyclic Compounds, 3-Ring / Q000627:therapeutic use; D006801:Humans; D010078:Oxazines; D010446:Peptide Fragments / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D010879:Piperazines; D011728:Pyridones; D000069616:Simeprevir; D000069474:Sofosbuvir; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014542:Uridine Monophosphate / Q000031:analogs & derivatives / Q000627:therapeutic use; D000099226:Dolutegravir
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005341:Fibrinolysin; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010446:Peptide Fragments; D010455:Peptides; D010879:Piperazines; D011728:Pyridones; D000069616:Simeprevir; D000069474:Sofosbuvir; D013004:Somatostatin; D013449:Sulfonamides; D014542:Uridine Monophosphate; D000099226:Dolutegravir; C542124:raxibacumab; C494910:teduglutide; C054561:microplasmin; C517782:pasireotide